Abstract:Human epidermal growth factor receptor 2 (HER2) belongs to the ErbB family, a group of four transmembrane glycoproteins with tyrosine kinase activity, all structurally related to epidermal growth factor receptor (EGFR). These tyrosine kinases are involved in the transmission of cellular signals controlling normal cell growth and differentiation. If this transmission goes awry, it can lead to dysregulated growth of the cell. HER2 specifically can be implicated in the pathogenesis of at least eight malignancies. HER2 positivity quickly became a well-characterized indicator of aggressiveness and poor prognosis, with high rates of disease progression and mortality. After realizing the implication of HER2, it first became investigated as a target for treatment in breast cancer, and later expanded to areas of research in other cancer types. To this day, the most therapeutic advancements of anti-HER2 therapy have been in breast cancer; however, there have been strong advancements made in the incorporation of anti-HER2 therapy in other cancer types as well. This comprehensive review dissects HER2 to its core, incorporating the most up to date information. The topics touched upon are discussed in detail and up to 200 published sources from the most highly recognized journals have been integrated. The importance of knowing about HER2 is exemplified by the groundbreaking advancements that have been made, and the change in treatment plans it has brought to the oncological world in the last twenty years. Since its groundbreaking discovery there have been significant breakthroughs in knowledge regarding the actual receptor, the receptors biology, its mechanism of action, and advancements in tests to detect HER2 and significant strides on how to best incorporate targeted treatment. Due to the success of this field thus far, the review concludes by discussing the future of novel anti-HER2 therapy currently in development that everyone should be aware of.

Research Progress of HER2 in Tumor Invasion and Metastasis

Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer

Modeling Time-Dependent Transcription Effects Of Her2 Oncogene And Discovery Of A Role For E2f2 In Breast Cancer Cell-Matrix Adhesion

Recent Progress in HER2 Associated Breast Cancer.

HER2 and Tumor Targeting Therapy

A Comprehensive Review of HER2 in Cancer Biology and Therapeutics

Advances in Research on Antitumor Activities of HER2-based Peptide Vaccines

Expression of HER-2 and Its Relationship with Pathological Characteristics and Tumor Angiogenesis in Human Breast Cancer

Effects of HER2 on the invasion and migration of gastric cancer.

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases

An Updated Review of the Research on Her-2-targeted Antibody Resistance Mechanisms

Recognition of HER2 expression in hepatocellular carcinoma and its significance in postoperative tumor recurrence

Research progress of epithelial-mesenchymal transition in cancer metastasis and stem cell

Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers

HER2-targeted Tumor immunotherapy

HER-2 promotes breast cancer cell epithelial-mesenchymal transition by regulating ZEB1

Expression and clinical significance of HER-2 in gastric cancer and metastastic lymph nodes

The expression of Her-2 in patients with pancreatic carcinoma and its significance

Research progress of epithelial-mesenchymal transformation-related transcription factors in peritoneal metastases

Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer

Role Of Her-2 Activity In The Regulation Of Malignant Meningioma Cell Proliferation And Motility